Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2017 | Research article

Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome

Authors: Jinjin Zhang, Xianhao Wu, Peizhen Gao, Pingping Yan

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Abstract

Background

The aim of this study was to evaluate the predictive value of cystatin C (CysC) and estimated glomerular filtration rate (eGFR) regarding vascular lesions and their severity in patients with acute coronary syndrome (ACS).

Methods

According to the results of coronary angiography, 195 ACS patients were divided into a single-vascular-lesion group (91 cases), a dual-vascular-lesion group (67 cases), and a multiple-vascular-lesion group (37 cases) to assess the severity of coronary artery disease according to Gensini scores and to analyze the correlations of CysC and eGFR level with vascular lesions and severity in ACS patients.

Results

Intergroup comparisons of univariate and multivariate regression analyses showed that CysC was positively correlated with vascular lesions (P < 0.05), but eGFR showed no correlation. Regarding the severity of vascular lesions, CysC was positively correlated with Gensini score (Pearson’s correlation coefficient r = 0.1811, P < 0.05), but eGFR was not correlated (P > 0.05).

Conclusions

Serum CysC levels could reflect the severity of vascular lesions in ACS patients, and a high CysC level had predictive value regarding the severity of vascular lesions in ACS.

Yang XH, Wang QX. Cystain C and research progess of cardiovescular disease. Clin Med. 2012;32:125–8.

Royakkers AA, Korevaar JC, van Suijlen JD, Hofstra LS, Kuiper MA, Spronk PE, et al. Serum and urine cystatin Care poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med. 2011;37:493–501.CrossRefPubMed

Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatinC with mortality, cardiovascular events and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173–9.CrossRefPubMed

Keler T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J. 2009;30:314–20.CrossRef

Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail. 2012;5:602–9.CrossRefPubMedPubMedCentral

Meng L, Yang Y, Qi LT, Wang XJ, Xu GB, Zhang BW. Eletated serum cyctatin C is an independent predictor of cardiovascular events in people with relatively nomal renal function. J Nephrol. 2012;25:426–30.CrossRefPubMed

He F, Zhang J, Lu ZQ, Gao QL, Sha DJ, Pei LG, et al. Risk factors and outcomes of acute kidney injury after intracoronary stent implantation. World J Emerg Med. 2012;3:197–201.CrossRefPubMedPubMedCentral

Doganer YC, Aydogan U, Aydogdu A, Aparci M, Akbulut H, Nerkiz P, et al. Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis. 2013;24:119–26.CrossRefPubMed

Doğaner YÇ, Aydoğan Ü, Rohrer JE, Aydoğdu A, Çaycı T, Barçın C, et al. Comparison of estimated GFR equations based on serum cystatin C alone and in combination with serum creatinine in patients with coronary aaery disease. Anatol J Cardiol. 2015;15:571–6.CrossRefPubMed

10.

Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.CrossRefPubMed

11.

Yu JH, Hu JZ, Zhou H, Liu X, Cao Q, Shen Y, et al. SCN5A mutation in patients with Brugada electrocardiographic pattern induced by fever. ZhonghuaXinXue Guan Bing ZaZhi. 2013;41:1010–4.

12.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Ciculation. 2002;105:1135–43.CrossRef

13.

Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede’ P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17:1128–37.CrossRefPubMed

14.

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62.PubMed

15.

Rao SK, Reddy KV, Cohen JR. Role of serine proteases in aneurysm development. Ann N Y Acad Sci. 1996;800:131–7.CrossRefPubMed

16.

Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of elastolyticcathepsins S and K in human atheroma and regulation of their production in smooth muscles cells. J Chin Invest. 1998;102:576–83.CrossRef

17.

Abdallah E, Waked E, Al-Helal B, Asad R, Nabil M, Harba T. Novel troponin-like biomarkers of acute kidney injury. Saudi J Kidney Dis Transpl. 2013;24:1111–24.CrossRefPubMed

18.

Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59:1148–56.CrossRefPubMedPubMedCentral

19.

Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, et al. Mildrenal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation. 2013;127:988–96.CrossRefPubMedPubMedCentral

20.

Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32:644–8.CrossRefPubMed

21.

Negrusz-Kawecka M, Poręba R, Hulok A, Sciborski K, Marczak J, Bańkowski T. Evaluation of the significance of cystatin C levels in patients suffering from coronary artery disease. Adv Clin Exp Med. 2014;23:551–8.CrossRefPubMed

22.

Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–8.CrossRefPubMed

23.

Tebaldi M, Biscaglia S, Fineschi M, Manari A, Menozzi M, Secco GG, et al. Flow reserve evaluation and chronic kidney disease: analysis from a multicenter Italian registry (the FREAK Study). Catheter Cardiovasc Interv. 2016;88:555–62.CrossRefPubMed

24.

Corpus RA, House JA, Marso SP, Grantham JA, Huber Jr KC, Laster SB, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J. 2004;148:493–500.CrossRefPubMed

25.

Sai E, Miyauchi K, Kojima T, Masaki Y, Kojima T, Miyazaki T, et al. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Heart Vessels. 2016;31:694–701.CrossRefPubMed

26.

Noto D, Cefalu AB, Barbagallo CM, Pace A, Rizzo M, Marino G, et al. Cystatin C levels are decreased in acutemyocardial infarction, effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol. 2005;101:213–7.PubMed

27.

Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atheroscler-osis and aortic aneurysms. J Chin Invest. 1999;104:1191–7.CrossRef

28.

Luc G, Bard JM, Lesueur C. Plasmacystatin-C and development of coronary heartdisease: The PRIME Study. Atherosclerosis. 2006;85:375–80.CrossRef

Title: Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome
Authors: Jinjin Zhang
Xianhao Wu
Peizhen Gao
Pingping Yan
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-017-0483-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Effects of cardiac telerehabilitation in patients with coronary artery disease using a personalised patient-centred web application: protocol for the SmartCare-CAD randomised controlled trial

Pre- and post-surgical evaluation of the inflammatory response in patients with aortic stenosis treated with different types of prosthesis

Complete ophthalmoplegia, complete ptosis and dilated pupil due to internal carotid artery dissection: as the first manifestation of Takayasu arteritis

Introduction of a novel service model to improve uptake and adherence with cardiac rehabilitation within Buckinghamshire Healthcare NHS Trust

Effect of increased left ventricle mass on ischemia assessment in electrocardiographic signals: rabbit isolated heart study

The utility of personal activity trackers (Fitbit Charge 2) on exercise capacity in patients post acute coronary syndrome [UP-STEP ACS Trial]: a randomised controlled trial protocol

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page